Kenda Šuster Nataša, Frković Grazio Snježana, Virant-Klun Irma, Verdenik Ivan, Smrkolj Špela
Division of Gynecology and Obstetrics, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Int J Gynecol Cancer. 2017 Nov;27(9):2006-2013. doi: 10.1097/IGC.0000000000001105.
The objectives of this study were to assess cancer stem cell-related marker NANOG expression in ovarian serous tumors and to evaluate its prognostic significance in relation to ovarian serous carcinoma.
NANOG protein expression was immunohistochemically evaluated in the ovarian tissue microarrays of 20 patients with benign ovarian serous tumors, 30 patients with borderline ovarian serous tumors, and 109 patients with ovarian serous carcinomas, from which 106 were of high-grade and 3 of low-grade morphology Immunohistochemical reaction was scored according to signal intensity and the percentage of positive cells in tumor samples. Pursuant to our summation of signal intensity and positive cell occurrence, we divided our samples into 4 groups: NANOG-negative, NANOG-slightly positive, NANOG-moderately positive, and NANOG-strongly positive group. Complete clinical data were obtained for the ovarian serous carcinoma group, and correlation between clinical data and NANOG expression was analyzed.
A specific brown nuclear, or cytoplasmic reaction, was considered a positive NANOG staining. In terms of the ovarian serous carcinoma group, 69.7% were NANOG positive, 22.9% slightly positive, 22.9% moderately positive, and 23.9% strongly positive. All NANOG-positive cases were of high-grade morphology. Benign and borderline tumors and low-grade serous carcinomas were NANOG negative. There was no significant correlation between NANOG expression and clinical parameters in terms of the ovarian serous carcinoma group.
Positive NANOG expression is significantly associated with high-grade ovarian serous carcinoma and is absent in benign, borderline, and low-grade serous lesions. In our study, there was no correlation between NANOG expression and clinical parameters, including its use in the prognosis of ovarian serous carcinoma.
本研究旨在评估癌症干细胞相关标志物NANOG在卵巢浆液性肿瘤中的表达，并评估其与卵巢浆液性癌相关的预后意义。
采用免疫组织化学方法评估20例卵巢浆液性良性肿瘤、30例卵巢浆液性交界性肿瘤和109例卵巢浆液性癌患者的卵巢组织芯片中NANOG蛋白的表达，其中106例为高级别形态，3例为低级别形态。根据肿瘤样本中信号强度和阳性细胞百分比对免疫组织化学反应进行评分。根据信号强度和阳性细胞出现情况的总和，将样本分为4组：NANOG阴性、NANOG轻度阳性、NANOG中度阳性和NANOG强阳性组。获取卵巢浆液性癌组的完整临床数据，并分析临床数据与NANOG表达之间的相关性。
特异性棕色核或细胞质反应被视为NANOG染色阳性。在卵巢浆液性癌组中，69.7%为NANOG阳性，22.9%为轻度阳性，22.9%为中度阳性，23.9%为强阳性。所有NANOG阳性病例均为高级别形态。良性和交界性肿瘤以及低级别浆液性癌为NANOG阴性。在卵巢浆液性癌组中，NANOG表达与临床参数之间无显著相关性。
NANOG阳性表达与高级别卵巢浆液性癌显著相关，在良性、交界性和低级别浆液性病变中不存在。在我们的研究中，NANOG表达与临床参数之间无相关性，包括其在卵巢浆液性癌预后中的应用。
